Revvity, Inc splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 28, 2025 was Life Sciences at $1.4 billion, 50% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 28, 2025 was Product at $2.4 billion, 84% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 5, 2026
|
FY 2025
Dec 28, 2025
|
FY 2024
Dec 29, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Jan 1, 2023
|
FY 2021
Jan 2, 2022
|
FY 2020
Jan 3, 2021
|
FY 2019
Dec 29, 2019
|
FY 2018
Dec 30, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Jan 1, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,912
|
2,856
|
2,755
|
2,751
|
3,312
|
3,828
|
2,663
|
2,884
|
2,778
|
2,257
|
2,116
|
| Operating segments | |||||||||||
| Life Sciences |
1,445
+1.8%
share 49.6%
|
1,431
+2.3%
share 50.1%
|
1,399
-4.1%
share 50.8%
|
1,458
+12.8%
share 53.0%
|
1,293
+44.3%
share 39.0%
|
896
share 23.4%
|
—
|
—
|
—
|
—
|
—
|
| Diagnostics |
1,466
+6.4%
share 50.4%
|
1,425
+5.1%
share 49.9%
|
1,356
+5.0%
share 49.2%
|
1,292
-36.0%
share 47.0%
|
2,019
-31.1%
share 61.0%
|
2,932
+41.8%
share 76.6%
|
2,067
+81.7%
share 77.6%
|
1,138
+4.9%
share 39.4%
|
1,085
+59.9%
share 39.0%
|
679
share 30.1%
|
—
|
| Sales mix | |||||||||||
| Product |
2,405
+1.5%
share 82.6%
|
2,390
+2.2%
share 83.7%
|
2,338
-3.2%
share 84.9%
|
2,416
-8.3%
share 87.8%
|
2,635
-3.7%
share 79.6%
|
2,735
-1.6%
share 71.5%
|
2,779
+37.8%
share 104.3%
|
2,017
+4.2%
share 69.9%
|
1,935
+31.0%
share 69.7%
|
1,477
share 65.5%
|
—
|
| Services |
507
+18.3%
share 17.4%
|
466
+11.8%
share 16.3%
|
417
+24.5%
share 15.1%
|
335
-50.6%
share 12.2%
|
677
-38.0%
share 20.4%
|
1,093
+8.8%
share 28.5%
|
1,004
+15.9%
share 37.7%
|
867
+2.9%
share 30.1%
|
843
+8.1%
share 30.3%
|
780
share 34.5%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- RVTY (NYSE)
- Fiscal year ends
- December 29
- Incorporated in
- MA
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 31791
- Former names
- PERKINELMER INC (until Apr 14, 2023); EG&G INC (until Jul 26, 1999)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
- 10x Genomics, Inc. TXG
Source: SEC EDGAR filings. This is company-reported data, not investment advice.